Hengrui PD-1 was officially approved as a clinical.

On January 9, the CDE Clinical Implied License column was updated with the approval of henri PD-1 (Carillizumab) for a clinical: in combination with albumin yewol and apatinib, for locally advanced or metastatic triple-negative breast cancers that were previously surgically removable for recurrent metastatic stages that were not treated with systemic anti-tumor treatment.

May 29, 2019, The PD-1 inhibitor Carillizumab (Erica) developed by Hengrui Pharmaceuticals was officially approved by the State Drug Administration for the treatment of patients with recurrent or refractive classic Hodgkin lymphoma who have undergone second-line system chemotherapy.
Carelli zhu monosarminoma was successfully approved, although it is the third domestic, but the force after the incalculable, the current Carelli Zhu monotophoid in addition to the approved Hodgkin's lymphoma indication, there are 3 new indications have been reported, respectively: liver cell cancer, non-scale non-small cell lung cancer and esophageal squamous cancer, are the domestic incidence of relatively high diseases.in addition, the Insight database shows that there are 31 clinical trials (according to clinical registration numbers) involving esophageal cancer, hepatocellular cancer, non-small cell lung cancer, small cell lung cancer, small cell lung cancer, and other cancers.
9 are in Phase III clinical work and 14 are in Phase II clinical practice.
Table 3 Karelli Zuma Synthe sediton seofa ongoing clinical trials and progress
Note: Remove duplicate registrations, there are 31 ongoing clinical trials (statistics: January 9, 2020) Original title: Hengrui PD-1 joint white purple and apatinib approved clinical trials, 31 clinical synchronization.